Form 4: Hims & Hers CEO Andrew Dudum Sells Over 50,000 Shares Under Pre-Arranged Trading Plan

Hims & Hers Health, Inc. CEO Andrew Dudum sold 50,326 shares of Class A Common Stock on July 16, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew Dudum, who serves as Chief Executive Officer, Director, and a 10% Owner of Hims & Hers Health, Inc. (HIMS), sold a total of 50,326 shares of Class A Common Stock.
• The transactions occurred on July 16, 2025, and were executed pursuant to a Rule 10b5-1 trading plan that was adopted on August 28, 2024.
• The shares were sold at weighted average prices: 2,792 shares at $50.579 (ranging from $50.47 to $50.745), 1,458 shares at $50.8213 (ranging from $50.79 to $50.89), and 46,076 shares at $50.237 (ranging from $49.80 to $50.785).
• Following these sales, Andrew Dudum directly holds 92,313 shares of Class A Common Stock.
• Indirect beneficial ownership after the transactions totals 10,039,241 shares held through various trusts, including the Dudum Family Community Property Trust, AD 2022 GRAT 3, Andrew Dudum 2015 Trust, AD 2021 GRAT, AD 2022 GRAT, AD 2025 GRAT 3, AD 2021 GRAT 2, AD 2023 GRAT, AD 2022 GRAT 2, and Dudum Family Heritage Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it was pre-planned via a 10b5-1 plan, which mitigates negative interpretations. The sale occurred at a relatively high share price, suggesting the insider capitalized on favorable market conditions.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned transaction for diversification or liquidity rather than a reaction to immediate market conditions or new information.
• Shares were sold at relatively high prices, with weighted averages exceeding $50 per share, suggesting the executive capitalized on favorable market valuation.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive in the company.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider stock sale by the CEO of Hims & Hers Health, Inc. under a pre-arranged trading plan. Such sales are common for executives for personal financial planning and diversification, and do not inherently reflect on the company's operational performance or broader industry trends in the telehealth sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived differently by investors; however, the use of a 10b5-1 plan suggests a pre-planned, non-discretionary sale, which typically has less negative impact than an unannounced, discretionary sale.

Key Dates

Recommendation

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, CEO, Beneficial Ownership